PeptideDB

MYLS22

CAS No.: 306959-01-3

MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to cur
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.
In vivo MYLS22(10 mg/kg/天;肿瘤周围注射;每2天一次,连续14天)能够抑制小鼠的肿瘤生长。
molecular weight 443.52
Molecular formula C24H21N5O2S
CAS 306959-01-3
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility DMSO: 45 mg/mL (101.46 mM), Sonication is recommended.
References 1. Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.